Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

Tang discusses the limitations in available data, but nonetheless high potential, of SBRT in kidney cancer. As Tang noted in his ASTRO 2024 presentation topic, SBRT has been linked to significantly ...

"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO. The rationale for this study is ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

“We need to close that gap, and just as a general rule, screen our prostate cancer patients more closely for depression, especially those with androgen deprivation therapy,” says Mihir S. Shah, MD. In ...

The study evaluates Focal One robotic HIFU for BPH, focusing on safety and efficacy in a phase 1/2 trial. Phase 1 determines optimal treatment parameters, while phase 2 expands enrollment to assess ...

Aquablation offers a versatile treatment for BPH, accommodating various prostate sizes and shapes, with a relatively flat learning curve for urologists. Proper patient selection is crucial for ...

Chemotherapy is often selected for aggressive or advanced-stage cancers requiring rapid tumor reduction. Patients with specific genetic mutations may benefit more from targeted therapies than ...

Aquablation with HYDROS is a transurethral water jet procedure for BPH, combining resective and non-resective therapy benefits. The HYDROS system uses AI-powered treatment planning and real-time ...

Androgen deprivation therapy significantly increases depression risk in prostate cancer patients, with a 60% higher incidence rate. White patients on androgen deprivation therapy are more likely to be ...

Chemotherapy, particularly docetaxel, significantly influences the adverse event profile, with common side effects including neutropenia, fatigue, and diarrhea. The ARASENS trial findings align with ...

"We remain on track for the opening of phase 2 in the next few months. We also expect to see the full phase 1 results presented at a scientific meeting in 2025," says David E. Gauden, DPhil. Lutetium ...